6.50
-0.25(-3.70%)
Currency In USD
| Previous Close | 6.75 |
| Open | 6.66 |
| Day High | 6.74 |
| Day Low | 6.46 |
| 52-Week High | 9.6 |
| 52-Week Low | 2.54 |
| Volume | 842,919 |
| Average Volume | 1.32M |
| Market Cap | 485.2M |
| PE | -12.04 |
| EPS | -0.54 |
| Moving Average 50 Days | 8.01 |
| Moving Average 200 Days | 5.58 |
| Change | -0.25 |
If you invested $1000 in Corvus Pharmaceuticals, Inc. (CRVS) since IPO date, it would be worth $456.14 as of January 14, 2026 at a share price of $6.5. Whereas If you bought $1000 worth of Corvus Pharmaceuticals, Inc. (CRVS) shares 5 years ago, it would be worth $1,573.85 as of January 14, 2026 at a share price of $6.5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference
GlobeNewswire Inc.
Jan 05, 2026 1:30 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, confirms the planned announcement of the results from cohort 4 of the randomized, blinded, place
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial
GlobeNewswire Inc.
Dec 08, 2025 3:30 PM GMT
Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 1 tri
Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition
GlobeNewswire Inc.
Nov 03, 2025 2:02 PM GMT
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that final data from its Phase 1/1b trial of soquelitinib in patients with T cel